Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q3GV
|
||||
| Former ID |
DPR000103
|
||||
| Drug Name |
S32504
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Preclinical | [1] | ||
| Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Terminated | [2] | |||
| Company |
Shionogi
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H22N2O2
|
||||
| Canonical SMILES |
CCCN1CCOC2C1CCC3=C2C=C(C=C3)C(=O)N
|
||||
| InChI |
1S/C16H22N2O2/c1-2-7-18-8-9-20-15-13-10-12(16(17)19)4-3-11(13)5-6-14(15)18/h3-4,10,14-15H,2,5-9H2,1H3,(H2,17,19)/t14-,15-/m1/s1
|
||||
| InChIKey |
XKTRZPQOQOCNJU-HUUCEWRRSA-N
|
||||
| CAS Number |
CAS 220932-72-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Modulator | [1] | |
| D(2) dopamine receptor | Target Info | Modulator | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Dopaminergic synapsehsa04015:Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| References | |||||
| REF 1 | S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. Epub 2004 Feb 20. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012906) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.